Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(12 sites)

United States

UCI Health - CIACC, Irvine, California

UC Irvine - Chao Family Cancer Center, Orange, California

Regis Clinical Research, Miami, Florida

Dana Farber Cancer Institute, Boston, Massachusetts

NYU Langone Health, Mineola, New York

Northwell Physician Partners Dermatology, New Hyde Park, New York

Montefiore Medical Center, The Bronx, New York

Gabrail Cancer & Research Center, Canton, Ohio

MD Anderson Cancer Center, Houston, Texas

Poland

Centrum Medyczne Pratia Krakow, Krakow

NZOZ Neuromed M. i M. Nastaj Sp.P, Lublin

Spain

Hospital Sant Joan de Deu-Fundacio Althaia, Manresa